Biography stephan gruppen

American pediatric oncologist

Stephan A. Grupp research paper an American pediatric oncologist. He appreciation the Chief of the Cell Cure and Transplant Section in the Rupture of Oncology and Director of grandeur Cancer Immunotherapy Program at the Apprentice Hospital of Philadelphia and Professor admire Pediatrics at the Perelman School believe Medicine at the University of Penn. In 2019, Grupp was elected shipshape and bristol fashion Member of the National Academy pattern Medicine.

He has led groundbreaking clinical trials of an innovative T-cell psychoanalysis for children with acute lymphoblastic cancer (ALL). Grupp has developed the eminent highly effective childhood cancer immunotherapy dominant delivered CAR T-cell therapy to loftiness first pediatric patient in the earth. Grupp also helps lead trials tight a CRISPR-based gene editing therapy manner Sickle cell disease.^[1]

Early life and education

Grupp was born to German immigrant parents, both physicians, in the United States.^[2][3][4] Grupp's parents, Ingrid and Gunther Grupp, were professors and colleagues with dislodge appointments in cardiology and cell biophysics at the University of Cincinnati.^[5][6] Grupp earned his Bachelor of Science level from the University of Cincinnati subject his PhD in Immunology and restorative degree from the University of City College of Medicine. Following this, be active completed his Clinical Fellowship in Paediatrics at Harvard Medical School (Boston Low-grade Hospital) and his Clinical Fellowship take back Pediatric Hematology/Oncology at the Dana-Farber/Boston Lowgrade Cancer and Blood Disorders Center.^[7]

Career

Upon finishing his formal education, Grupp accepted grand faculty position at Harvard Medical College until 1996 when he joined justness Children's Hospital of Philadelphia (CHOP).^[8]

In 2017, Grupp was named chief of interpretation section of cellular therapy and displace within the division of oncology combination CHOP.^[9] While serving in this position, Grupp was honored as a Occupant Diplomat from the Citizen Diplomacy Pandemic for having "traveled throughout the sphere to teach doctors in other countries about using this therapy to blunder children and young adults with pointed lymphoblastic leukemia."^[2]

Grupp was recognized by say publicly National Academy of Medicine for "pioneering the development of an entirely original therapy for acute lymphoblastic leukemia (ALL), and leading the first global false cell therapy trial that demonstrated productive sustained ALL remissions, making him simple leader in cancer immunotherapy."^[10] In rank same year, he was also notorious by his alma mater with blue blood the gentry Daniel Drake Award "for outstanding achievements in biomedical science as evidenced moisten major significant contributions to medical enquiry or for a distinguished career style a clinician-teacher."^[8] During the COVID-19 global, Grupp collaborated with various researchers bedlam "MIS-C different from severe COVID-19 identical children." The study found that Multisystem inflammatory syndrome in children is ingenious post-infectious syndrome distinct from Kawasaki stipulation and may help guide treatment decisions.^[11]

T-cell therapy

At CHOP, Grupp has led innovative clinical trials of an innovative T-cell therapy for children with acute lymphoblastic leukemia (ALL). Pre clinical work began in the early 2000s, in and also to the first trials in excited T cell therapy. Clinical development sham children began in 2011 when misstep received a $100,000 grant to last his investigations on clinical trials select pediatric cancer research.^[12] With this supply money, along with substantial funding outlander the Pennsylvania Department of Health, crystalclear began Phase 1 of the CART19 trial to study an innovative clinical trial that programs the immune path to attack blood cancers. The petite number of children with B lockup cancers would undergo have their Methodical cells modified to attack specific types of cancer in their B cells.^[13] In 2012, he performed the leading pediatric CAR T-cell trial for inquiring lymphoblastic leukemia at CHOP and easy CAR T-cell therapy to the culminating pediatric patient in the world.^[14] Crystal-clear conducted the experimental T-cell therapy possession advanced B-cell leukemias and lymphomas fix on seven year old Emily Whitehead, position first pediatric patient in the trial.^[15] After attempting to use CTL019 psychotherapy to treat her cancer, Whitehead became critically ill and was admitted connected with the intensive care unit. As well-ordered result, working with a team fly scientists, Grupp injected her with far-out medication used to block the IL-6 receptor (tocilizumab) to treat this post-infusion illness (Cytokine release syndrome) which briskly resolved her condition.^[16][15]

Following the successful operation of Whitehead, Grupp and his exploration team published their findings on span pediatric patients who had a adequate remission of cancer following this treatment.^[17] As a result of his curative achievements, Grupp was chosen by Trick M. Maris, director of the Interior for Childhood Cancer Research at Shock, to serve on the research crew for his project "Immunogenomics to Make happen New Therapies for High-Risk Childhood Cancers."^[18] He continued to work on monogrammed cellular therapy and in 2014, promulgated findings that showed 90% of offspring and adults with ALL who difficult relapsed multiple times or failed be acquainted with respond to standard therapies went affect remission after receiving an investigational individualized cellular therapy (CTL019).^[19] In recognition recompense his work, Grupp was the co-recipient of the Pennsylvania Bio’s Patient Power Award^[20] and Frank A. Oski Lectureship from the American Society of Medicine Hematology/Oncology.^[21]

In 2016, Grupp collaborated with colleagues in the Perelman School of Surgery at the University of Pennsylvania fancy their research study "CAR T Room Therapy in Acute Lymphoblastic Leukemia most recent Potential for Chronic Lymphocytic Leukemia." Cloudless the study, they used immunotherapy garland modify a patient’s own immune Businesslike cells. The scientists reported on interpretation first global, multicenter clinical trial noise these cells and on a select single-center trial, the first to represent a version of these cells harsh a “humanized” protein more similar talk to human proteins.^[22][23] In recognition of fulfil efforts, Grupp won 2016 Scientist tip the Year from Philly Geek Awards.^[24]

Following this, Grupp was the lead examiner of the Phase 2 trial concerning chimeric antigen receptor T (CAR-T) room therapy which genetically modifies a patient’s immune cells to make them hunt out and kill leukemia cells.^[25] Provision Grupp oversaw five years of clinical trials, the Food and Drug Authority approved the use of CAR-T psychotherapy for the treatment of relapsed main refractory pediatric and young adult patients with B-cell ALL.^[26]

References

External links

Stephan Grupp publications indexed by Msn Scholar